18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: Relation to tumor differentiation

Journal of Nuclear Medicine

Volumn 49, Issue 4, 2008, Pages 524-531

  Koopmans, Klaas P ^a   De Groot, Jan Willem B ^a   Plukker, John T M ^a   De Vries, Elisabeth G E ^a   Kema, Ido P ^a   Sluiter, Wim J ^a   Jager, Pieter L ^a   Links, Thera P ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

18F DOPA; 18F FDG; Calcitonin; Medullary thyroid cancer; PET; Tumor differentiation; Tumor markers

Indexed keywords

CALCITONIN; CARCINOEMBRYONIC ANTIGEN; DIHYDROXYPHENYLALANINE F 18; FLUORODEOXYGLUCOSE F 18; SUCCIMER TC 99M; TRACER; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; DOPA; FLUORINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CALCITONIN BLOOD LEVEL; CANCER DIAGNOSIS; CANCER MORPHOLOGY; CANCER PATIENT; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; THYROID CANCER; TUMOR DIFFERENTIATION; BLOOD; MEDULLARY CARCINOMA; METHODOLOGY; MIDDLE AGED; PATHOLOGY; SCINTISCANNING; THYMOMA;

ADULT; AGED; CALCITONIN; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, MEDULLARY; DIHYDROXYPHENYLALANINE; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; THYMUS NEOPLASMS;

EID: 42049103697     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.107.047720     Document Type: Article

References (32)

1. Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer. 2000;88:1139-1148.
2. Orlandi F, Caraci P, Mussa A, et al. Treatment of medullary thyroid carcinoma: an update. Endocr Relat Cancer. 2001;8:135-147.
3. de Groot JW, Plukker JT, Wolffenbuttel BH, et al. Determinants of life expectancy in medullary thyroid cancer: age does not matter. Clin Endocrinol (Oxf). 2006;65:729-736.
4. 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. J Nucl Med. 2007;48:501-507.
5. Moley JF, DeBenedetti MK. Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann Surg. 1999;229:880-887.
6. Scollo C, Baudin E, Travagli JP, et al. Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab. 2003;88:2070-2075.
7. de Groot JW, Links TP, Sluiter WJ, et al. Locoregional control in patients with palpable medullary thyroid cancer: results of standardized compartment-oriented surgery. Head Neck. 2007;29:857-863.
8. Cohen EG, Shaha AR, Rinaldo A, Devaney KO, Ferlito A. Medullary thyroid carcinoma. Acta Otolaryngol. 2004;124:544-557.
9. 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer. Ann Surg Oncol. 2004;11:786-794.
10. Khan N, Oriuchi N, Higuchi T, Endo K. Review of fluorine-18-2-fluoro-2- deoxy-D-glucose positron emission tomography (FDG-PET) in the follow-up of medullary and anaplastic thyroid carcinomas. Cancer Control. 2005;12:254-260.
11. Uchino H, Kanai Y, Kim DK, et al. Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition. Mol Pharmacol. 2002;61:729-737.
12. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med. 2001;28:64-71.
13. 18F]-fluorodopamine positron emission tomography. J Clin Endocrinol Metab. 2003;88:637-641.
14. 18F]-fluoro-L-DOPA. Appl Radiat Isot. 1999;51:389-419.
15. Brown WD, Oakes TR, DeJesus OT, et al. Fluorine-18-fluoro-L-DOPA dosimetry with carbidopa pretreatment. J Nucl Med. 1998;39:1884-1891.
16. Ishikawa T, Dhawan V, Chaly T, et al. Fluorodopa positron emission tomography with an inhibitor of catechol-O-methyltransferase: effect of the plasma 3-O-methyldopa fraction on data analysis. J Cereb Blood Flow Metab. 1996;16:854-863.
17. 11C-5- hydroxytryptophan positron emission tomography. Eur J Nucl Med Mol Imaging. 2006;33:60-65.
18. 18F-DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol. 2006;7:728-734.
19. Miyauchi A, Onishi T, Morimoto S, et al. Relation of doubling time of plasma calcitonin levels to prognosis and recurrence of medullary thyroid carcinoma. Ann Surg. 1984;199:461-466.
20. 18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2007;34:1604-1609.
21. 18F]FDG in the imaging of small cell lung carcinoma: preliminary results. Eur J Nucl Med Mol Imaging. 2003;30:1266-1269.
22. Timmers HJ, Kozupa A, Chen CC, et al. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol. 2007;25:2262-2269.
23. Gimm O, Ukkat J, Dralle H. Determinative factors of biochemical cure after primary and reoperative surgery for sporadic medullary thyroid carcinoma. World J Surg. 1998;22:562-567.
24. Machens A, Holzhausen HJ, Dralle H. Prediction of mediastinal lymph node metastasis in medullary thyroid carcinoma. Br J Surg. 2004;91:709-712.
25. Kebebew E, Kikuchi S, Duh QY, Clark OH. Long-term results of reoperation and localizing studies in patients with persistent or recurrent medullary thyroid cancer. Arch Surg. 2000;135:895-901.
26. Machens A, Hinze R, Lautenschlager C, Thomusch O, Dralle H. Thyroid carcinoma invading the cervicovisceral axis: routes of invasion and clinical implications. Surgery. 2001;129:23-28.
27. Moley JF, DeBenedetti MK. Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann Surg. 1999;229:880-887.
28. Bergholm U, Bergstrom R, Ekbom A. Long-term follow-up of patients with medullary carcinoma of the thyroid. Cancer. 1997;79:132-138.
29. Machens A, Holzhausen HJ, Dralle H. Contralateral cervical and mediastinal lymph node metastasis in medullary thyroid cancer: systemic disease? Surgery. 2006;139:28-32.
30. Hicks RJ, Ware RE, Lau EW. PET/CT: will it change the way that we use CT in cancer imaging? Cancer Imaging. 2006;31(suppl):S52-S62.
31. Behr TM, Jenner N, Radetzky S, et al. Targeting of cholecystokinin-B/ gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin. Eur J Nucl Med. 1998;25:424-430.
32. Gotthardt M, Behe MP, Beuter D, et al. Improved tumour detection by gastrin receptor scintigraphy in patients with metastasised medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2006;33:1273-1279.